AVITA Medical Launches Cohealyx for Wound Healing in the US
Shots:
- AVITA Medical has launched Cohealyx, collagen-based dermal matrix in the US
- Cohealyx is currently being evaluated in the post-market Cohealyx I trial (enrolment ongoing) to further assess clinical outcomes, wound bed preparation for definitive closure, & patient recovery timelines
- Cohealyx, developed by AVITA & Regenity Biosciences, is designed to support cellular migration & revascularization, allowing formation of an optimal wound bed for closure, with preclinical & early clinical data showing integrated wound bed formation as early as 7 days
Ref: Globenewswire | Image: AVITA Medical
Related News:- The US FDA Grants 510(k) Clearance to Medivis’ Spine Navigation Platform
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
